Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Sarl boosted its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 10.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 148,559 shares of the company’s stock after acquiring an additional 14,635 shares during the period. BeOne Medicines accounts for about 0.9% of Capital International Sarl’s portfolio, making the stock its 29th biggest position. Capital International Sarl owned about 0.14% of BeOne Medicines worth $50,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Primecap Management Co. CA bought a new position in shares of BeOne Medicines in the second quarter valued at approximately $1,231,720,000. Capital International Investors raised its position in BeOne Medicines by 3.3% in the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after acquiring an additional 161,052 shares during the period. Temasek Holdings Private Ltd purchased a new position in shares of BeOne Medicines in the second quarter valued at $244,603,000. Marshall Wace LLP bought a new position in shares of BeOne Medicines in the second quarter worth approximately $113,190,000. Finally, Baird Financial Group Inc. purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth about $82,895,000. 48.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO John Oyler sold 24,369 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $302.87, for a total value of $7,380,639.03. The SEC filing for this sale provides additional information. Insiders have sold 102,656 shares of company stock valued at $31,567,496 over the last 90 days. 6.62% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ONC has been the subject of a number of research reports. Royal Bank Of Canada increased their target price on BeOne Medicines from $417.00 to $425.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Barclays lifted their price objective on BeOne Medicines from $394.00 to $405.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Citigroup boosted their price target on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Truist Financial increased their target price on BeOne Medicines from $400.00 to $412.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Guggenheim boosted their price objective on shares of BeOne Medicines from $400.00 to $410.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $401.00.

BeOne Medicines Price Performance

Shares of ONC stock opened at $302.29 on Tuesday. The firm has a fifty day simple moving average of $335.51 and a 200-day simple moving average of $330.31. The company has a market capitalization of $33.15 billion, a PE ratio of 119.96 and a beta of 0.53. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $196.45 and a twelve month high of $385.22. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The firm had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. Equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.